Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Filippo de Marinis"'
Publikováno v:
Expert opinion on therapeutic targets. 16
In EGFR mutated advanced NSCLC, tyrosine kinase inhibitors are new valid options as first-line treatment. Gefitinib appears a valid alternative to chemotherapy as first-line therapy, in EGFR mutated elderly or unfit patients too, while erlotinib rema